Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows

Moderna Inc. (NASDAQ:MRNA) is developing mRNA-1769 as a mpox vaccine for use in adults.

Currently, a Phase 1/2 trial evaluating the safety, tolerability, and immunogenicity of mRNA-1769 in Healthy Participants is underway. The 351-subject trial was started in 2023, and data is anticipated in 2025.

In a paper released in Cell, Moderna’s mRNA-1769 had been more effective than the Bavarian Nordic A/S (OTC:BVNRY) (OTC:BVNKF) Jynneos vaccine in preventing severe disease and reducing virus levels in monkeys.

Also read: Mpox Vaccines: Challenges Persist as Congo ...